Sanofi’s immunization strategy is taking shape, owing to an authorization that could drive the company and its partner AstraZeneca to the forefront of the respiratory syncytial virus (RSV) treatment battle. The FDA approved Sanofi and AstraZeneca’s monoclonal antibody Beyfortus, also known as nirsevimab, as a preventative for RSV lower respiratory tract disease in newborns on June 17. The approval includes newborns and infants born during or about to enter their first RSV season, as well as young children up to 24 months old who are still at risk of RSV during their second disease season.
The clearance places Sanofi and AstraZeneca in the RSV treatment market that ...
